Creative Medical Technology (CELZ) Projected to Post Earnings on Friday

Creative Medical Technology (NASDAQ:CELZ) is projected to announce its resultson Friday, November 6th. Analysts expect Creative Medical Technology to announce earnings of ($0.24) per share for the quarter.

Creative Medical Technology (NASDAQ:CELZ) last posted its earnings results on Friday, August 7th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.02). On average, analysts expect Creative Medical Technology to post ($1.18) EPS for the current fiscal year and ($0.88) EPS for the next fiscal year.

Creative Medical Technology Price Performance

Shares of NASDAQ CELZ opened at $0.65 on Thursday. The business’s 50 day moving average is $0.89 and its two-hundred day moving average is $1.56. Creative Medical Technology has a 52-week low of $0.60 and a 52-week high of $4.72.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on CELZ shares. Wall Street Zen raised Creative Medical Technology from a “sell” rating to a “hold” rating in a research note on Saturday, September 12th. Roth Capital reiterated a “buy” rating on shares of Creative Medical Technology in a report on Thursday, August 20th. Finally, Weiss Ratings lowered Creative Medical Technology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 24th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Creative Medical Technology currently has an average rating of “Hold”.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc is a biotechnology company focused on developing regenerative medicine and cellular therapies. Its research programs are designed to use stem cells and other biological approaches to address conditions for which existing treatment options may be limited.

The company has developed and investigated therapies based on autologous stem cells, meaning cells collected from and administered back to the same patient. Its programs have included CaverStem, a regenerative treatment candidate for erectile dysfunction, as well as investigational platforms such as FemCelz for female sexual dysfunction and ImmCelz, an immune-modulating cellular therapy platform.